Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rapacuronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.71 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.70 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.70 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rapacuronium SCHEMBL41132 | 0.99 | SLC22A2 (0.71) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Rapacuronium SCHEMBL1650924 | 0.99 | SLC22A2 (0.71) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Rapacuronium SCHEMBL10699459 | 0.99 | SLC22A2 (0.71) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Rapacuronium SCHEMBL9094653 | 0.99 | SLC22A2 (0.71) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Bromide SCHEMBL10698649 | 0.96 | SLC22A2 (0.71) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Bromide SCHEMBL10698645 | 0.96 | SLC22A2 (0.71) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Bromide SCHEMBL10700198 | 0.96 | SLC22A2 (0.65) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| Bromide SCHEMBL10700202 | 0.96 | SLC22A2 (0.65) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| SCHEMBL13851843 | 0.94 | KCNH2 (0.77) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 | |
| SCHEMBL13890594 | 0.94 | KCNH2 (0.77) | KCNH2HRH3SLC22A2SLC47A2SLC47A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| CN-111615522-B | Process for the synthesis of cyclodextrin derivatives | 摩迪康公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115916258-A | Glucocorticoid reducing agent | 麦翠奥制药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115768745-A | Sulfated columnar arenes, methods of making same, and uses thereof | 马里兰大学派克分院 | 2023-03-07 | — | — | CN | disclosed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-9956229-B2 | Acyclic cucurbit[n]uril type molecular containers to treat intoxication and decrease relapse rate in substance abuse disorders | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170246180-A1 | ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | GENERAL HOSPITAL CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-20170246180-A1 | ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | GENERAL HOSPITAL CORPORATION | 2017-08-31 | — | — | US | disclosed |
| EP-2900216-B1 | STABILIZED AQUEOUS COMPOSITIONS OF NEUROMUSCULAR BLOCKING AGENTS | BRAUN MELSUNGEN AG (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-9469648-B2 | Reversal of drug-induced neuromuscular block using novel molecular containers | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150216979-A1 | Stabilized Aqueous Compositions of Neuromuscular Blocking Agents | B. BRAUN MELSUNGEN AG (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150216979-A1 | Stabilized Aqueous Compositions of Neuromuscular Blocking Agents | B. BRAUN MELSUNGEN AG (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216979-A1 | Stabilized Aqueous Compositions of Neuromuscular Blocking Agents | TNNC1, GAP43, ACHE | KCNH2 11/4885HRH3 94/4885SLC22A2 2544/4885 |
| US-20170246180-A1 | ACYCLIC CUCURBIT[N]URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | CNR1, CNR2, OPRM1 | KCNH2 753/4885HRH3 826/4885SLC22A2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.